Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Oportun Financial price target lowered to $14 from $26 at JMP Securities » 06:52
05/15/20
05/15
06:52
05/15/20
06:52
OPRT

Oportun Financial

$6.00 /

-0.25 (-4.00%)

JMP Securities analyst…

JMP Securities analyst David Scharf lowered the firm's price target on Oportun Financial to $14 from $26 but keeps an Outperform rating on the shares. The analyst notes that the company beat on Q1 earnings when excluding the COVID-19-driven fair value write-down, and the management offered "the most complete disclosure of April and May volume, payment, and credit trends seen from any company thus far". Scharf remains positive on Oportun given the evidence of a more resilient borrower base and employment profile than feared, but his price target reflects a reduced expected FY21 earnings multiple of 7-times vs. 8-times prior.

ShowHide Related Items >><<
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

On The Fly
Fly Intel: After-Hours Movers » 19:11
05/14/20
05/14
19:11
05/14/20
19:11
YTEN

Yield10 Bioscience

$4.92 /

-0.02 (-0.40%)

, OPRT

Oportun Financial

$6.00 /

-0.25 (-4.00%)

, DENN

Denny's

$8.77 /

-0.035 (-0.40%)

, ACB

Aurora Cannabis

$6.61 /

+0.79 (+13.57%)

, AEYE

AudioEye

$8.88 /

+0.71 (+8.69%)

, NEWR

New Relic

$58.22 /

+1.62 (+2.86%)

, DDS

Dillard's

$22.94 /

-1.15 (-4.77%)

, AMAT

Applied Materials

$54.51 /

+2.98 (+5.78%)

, GLOB

Globant

$111.38 /

+3.1 (+2.86%)

, OCUL

Ocular Therapeutix

$6.01 /

-0.3 (-4.75%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

, CODX

Co-Diagnostics

$22.19 /

-1.2 (-5.13%)

, FTCH

Farfetch

$15.94 /

+0.35 (+2.25%)

, CVET

Covetrus

$11.25 /

+0.3 (+2.74%)

, ETON

Eton Pharmaceuticals

$5.20 /

+0.03 (+0.58%)

, AUPH

Aurinia Pharmaceuticals

$17.39 /

-0.19 (-1.08%)

, VVI

Viad

$16.65 /

+0.71 (+4.45%)

, TGTX

TG Therapeutics

$19.90 /

-0.72 (-3.49%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
DENN Denny's
$8.77 /

-0.035 (-0.40%)

04/08/20 Oppenheimer
Denny's price target lowered to $13 from $27 at Oppenheimer
04/01/20 SunTrust
El Pollo Loco upgraded to Buy from Hold at SunTrust
04/01/20 SunTrust
Denny's upgraded to Buy from Hold at SunTrust
03/20/20 Stephens
Denny's price target lowered to $12 from $19 at Stephens
ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

05/13/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$22 from C$2.75 at Cantor Fitzgerald
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

10/24/19 National Securities
AudioEye resumed with a Buy at National Securities
05/31/19 B. Riley FBR
AudioEye selloff brings 'compelling' entry point, syays B. Riley FBR
NEWR New Relic
$58.22 /

+1.62 (+2.86%)

04/27/20 Needham
New Relic price target lowered to $74 from $108 at Needham
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight amid weaker backdrop at Morgan Stanley
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight from Overweight at Morgan Stanley
04/06/20 Rosenblatt
New Relic initiated with a Neutral at Rosenblatt
DDS Dillard's
$22.94 /

-1.15 (-4.77%)

05/07/20 Deutsche Bank
Dillard's price target lowered to $18 from $36 at Deutsche Bank
04/30/20 Wedbush
Dillard's price target lowered to $25 from $63 at Wedbush
01/24/20 Odeon Capital
Dillard's initiated with a Sell at Odeon Capital
11/11/19 Deutsche Bank
L Brands downgraded to Hold from Buy at Deutsche Bank
AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

05/12/20 Susquehanna
Applied Materials fundamentals strong ahead of results, says Susquehanna
05/11/20 Cowen
Applied Materials sales trajectory has positive slope, says Cowen
05/08/20 Wells Fargo
Applied Materials price target raised to $60 from $50 at Wells Fargo
04/14/20 Deutsche Bank
Applied Materials share underperformance unwarranted, says Deutsche Bank
GLOB Globant
$111.38 /

+3.1 (+2.86%)

04/29/20 Goldman Sachs
Globant price target lowered to $130 from $165 at Goldman Sachs
04/16/20 Wedbush
Globant price target lowered to $120 from $150 at Wedbush
03/10/20 KeyBanc
Globant downgraded to Sector Weight from Overweight at KeyBanc
02/21/20 Cantor Fitzgerald
Globant price target raised to $120 from $97 at Cantor Fitzgerald
OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
03/04/20 Piper Sandler
Ocular Therapeutix price target raised to $11 from $7 at Piper Sandler
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
03/30/20 Wells Fargo
Farfetch downgraded to Underweight from Equal Weight at Wells Fargo
02/28/20 KeyBanc
Farfetch price target lowered to $17 from $20 at KeyBanc
11/15/19 Credit Suisse
Farfetch price target lowered to $17 from $22 at Credit Suisse
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

03/30/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $26 from $23 at H.C. Wainwright
01/28/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $23 from $21 at H.C. Wainwright
10/23/19 H.C. Wainwright
Eton Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
09/20/19
Fly Intel: Top five analyst initiations
AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

  • 15
    May
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

Earnings
Oportun Financial reports Q1 adj. EPS (4c), consensus 17c » 16:13
05/14/20
05/14
16:13
05/14/20
16:13
OPRT

Oportun Financial

$6.05 /

-0.205 (-3.28%)

Reports Q1 revenue…

Reports Q1 revenue $163.4M, consensus $163.95M. "Oportun is demonstrating its resiliency in this challenging environment as we remain focused and responsive to the needs of our customers and employees," said Raul Vazquez, CEO of Oportun. "The decisive and proactive actions to adapt our credit underwriting, enhance our customer servicing and manage our liquidity will help ensure that we can continue serving as many of our customers as possible, and I am confident that our company will be even stronger when this crisis finally recedes. I want to express my gratitude once again to our employees for living our values and making it possible to continue fulfilling our mission of serving our communities."

ShowHide Related Items >><<
OPRT Oportun Financial
$6.05 /

-0.205 (-3.28%)

OPRT Oportun Financial
$6.05 /

-0.205 (-3.28%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
OPRT Oportun Financial
$6.05 /

-0.205 (-3.28%)

Over a month ago
Recommendations
Oportun Financial price target lowered to $19 from $27 at BTIG » 08:16
04/07/20
04/07
08:16
04/07/20
08:16
OPRT

Oportun Financial

$7.20 /

+0.45 (+6.67%)

BTIG analyst Mark Palmer…

BTIG analyst Mark Palmer lowered the firm's price target on Oportun Financial to $19 from $27 but keeps a Buy rating on the shares. The analyst is lowering his Q2 EPS view on the company to (34c) from 52c to reflect the asignificant reduction in interest income due to deferred loan payments amid COVID-19 outbreak. Palmer also notes that his recent call with Oportun Financial management highlighted the insulated employment industries of some of the company's customers, with many also being supported by the direct payments of $1,200 authorized under the CARES Act.

ShowHide Related Items >><<
OPRT Oportun Financial
$7.20 /

+0.45 (+6.67%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG
Earnings
Oportun Financial withdraws FY20 guidance » 07:19
04/02/20
04/02
07:19
04/02/20
07:19
OPRT

Oportun Financial

$7.82 /

-2.63 (-25.17%)

The company said,…

The company said, "Given the ongoing uncertainty surrounding the duration and severity of COVID-19, Oportun is withdrawing its full year 2020 guidance. The Company anticipates its future financial performance will be impacted, but the magnitude and timing of this impact is too dependent on external factors to reliably set guidance parameters at this time. Oportun will continue to provide updated information as the impact of the pandemic becomes clearer."

ShowHide Related Items >><<
OPRT Oportun Financial
$7.82 /

-2.63 (-25.17%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG
Earnings
Oportun Financial withdraws Q1 adj. EBITDA, adj. net income guidance » 07:19
04/02/20
04/02
07:19
04/02/20
07:19
OPRT

Oportun Financial

$7.82 /

-2.63 (-25.17%)

The company said,…

The company said, "With respect to its first quarter 2020 guidance, Oportun is preliminarily projecting that Total Revenue and FVPF Total Revenue are both expected to be approximately $162 million. Annualized net charge offs for the quarter were 9.0%. Given the proximity to the end of the quarter, the Company is withdrawing its guidance for Adjusted EBITDA and Adjusted Net Income while it completes its quarter-close process."

ShowHide Related Items >><<
OPRT Oportun Financial
$7.82 /

-2.63 (-25.17%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG
Hot Stocks
Oportun Financial reports Q1 active customers 777,194 » 07:19
04/02/20
04/02
07:19
04/02/20
07:19
OPRT

Oportun Financial

$7.82 /

-2.63 (-25.17%)

The company said,…

The company said, "The Company ended the first quarter of 2020 with $5 million in auto loans and $2 million of credit card receivables issued through a partner bank, with $2 million open-to-buy. .Until the week of March 15, 2020, when Oportun first began to experience the economic impact of COVID-19, the Company was on track to deliver another strong quarter, including double-digit growth in originations compared to the prior year quarter. As previously described, Oportun proactively took measures to tighten its lending criteria and implement appropriate collections actions. Since that time, the Company has seen a reduction in applications, which it believes is attributable both to customers abiding by shelter-in-place orders as well as a redirection of marketing efforts. These measures impacted Oportun's Aggregate Originations, which were $433 million for the first quarter, up 4% from the prior-year period. The Company ended the quarter with 777,194 Active Customers and $2.2 billion in Managed Principal Balance at End of Period, up 11% and 20%, respectively, over the prior year."

ShowHide Related Items >><<
OPRT Oportun Financial
$7.82 /

-2.63 (-25.17%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG
Hot Stocks
Oportun Financial sees increase in early-stage delinquencies » 07:17
04/02/20
04/02
07:17
04/02/20
07:17
OPRT

Oportun Financial

$7.82 /

-2.63 (-25.17%)

The company said,…

The company said, "Oportun ended the first quarter of 2020 with a 30+ Day Delinquency Rate of 3.8% and an Annualized Net Charge-Off Rate of 9.0%, versus 3.6% and 8.3% respectively in the prior-year period. Because the Company offers a grace period, ranging between 7 and 15 days before a late fee is assessed, customers have extra time to make a payment, if needed. Oportun monitors its early stage delinquencies very closely and attempts to contact delinquent customers before the grace period expires to provide them with payment options. Oportun has seen an increase in early-stage delinquencies, with 8 to 14 day delinquencies and 15 to 29 day delinquencies of 2.2% and 1.8%, respectively, as of March 31, 2020 as compared to 1.2% and 1.5%, respectively as of March 31, 2019."

ShowHide Related Items >><<
OPRT Oportun Financial
$7.82 /

-2.63 (-25.17%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG
Hot Stocks
Oportun Financial continues to see 'strong' customer payment activity » 07:16
04/02/20
04/02
07:16
04/02/20
07:16
OPRT

Oportun Financial

$7.82 /

-2.63 (-25.17%)

The company said,…

The company said, "The Company remains committed to working with its customers during this uncertain time. Starting last week, the Company began offering initial hardship deferments of one month to customers who indicated they had been economically impacted by the COVID-19 pandemic. Consistent with recent regulatory guidance, Oportun may consider deferrals of up to 90 days, granted one month at a time, for borrowers who continue to be impacted. All of Oportun's collection activities continue to be centralized through multiple contact centers located in three different countries. The Company's contact centers have continued to meet all service levels, with an average time to answer a call of less than 10 seconds, despite significantly increased call volumes. Oportun believes that its contact centers in disbursed geographies, along with its cloud-based technology, position the Company well to react to suspension of operations at any contact center. Oportun has proactively increased its customer service and collections capacities through new hiring and cross-training of existing personnel. The Company continues to see strong customer payment activity. Over 67% of customers are making payments outside of Oportun's retail locations, with over 59% of all customers paying via ACH or debit card. Customers who prefer to pay in cash can continue to do so at Oportun's retail locations or at over 56,000 third-party payment locations such as Walmart, Family Dollar, CVS, Kroger and 7-Eleven. Customers can make a payment through any of these channels without paying a fee."

ShowHide Related Items >><<
OPRT Oportun Financial
$7.82 /

-2.63 (-25.17%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG
Hot Stocks
Oportun Financial says 341 retail locations remain open » 07:15
04/02/20
04/02
07:15
04/02/20
07:15
OPRT

Oportun Financial

$7.82 /

-2.63 (-25.17%)

The company said,…

The company said, "Oportun's significant investments in data science, risk analytics and engineering have allowed it to make rapid changes to its 100% centralized and fully automated credit underwriting platform. In anticipation of the impact of COVID-19, the Company proactively tightened its underwriting criteria and adjusted loan amounts overnight. Additionally, Oportun added new alternative data variables to its underwriting scorecard in under a week. Because of the Company's investments in technology, Oportun also rapidly implemented incremental changes to its pricing, servicing and collections capabilities. The Company believes its technological capabilities will allow it to continue to rapidly respond as the situation evolves. As a financial services provider, Oportun is deemed to be part of an "Essential Critical Infrastructure Sector" by the Department of Homeland Security, and the Company is expected to maintain its operations for essential personnel, even in geographies where shelter-in-place orders have been enacted. Additionally, financial regulators have encouraged lenders to offer responsible small-dollar loans to consumers impacted by COVID-19. For these reasons, as of March 31, 2020, 337 of the Company's 341 retail locations remain open to serve customers. Customers can also apply for a loan directly over the phone by calling Oportun's contact centers located in three different countries. Additionally, a customer can complete the entire lending process online via their mobile device through the Company's end-to-end mobile solution."

ShowHide Related Items >><<
OPRT Oportun Financial
$7.82 /

-2.63 (-25.17%)

01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
11/13/19 BTIG
Oportun Financial price target raised to $22 from $19 at BTIG

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.